Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. While the performance was in line with the expectations for the full year. The firm believes that the Strategy underperformed in 2025 because it did not own Palantir Technologies Inc (PLTR). The Strategy focuses on achieving solid risk-adjusted returns by investing in high-quality compounders with fair valuations and market capitalizations between $2 billion and $50 billion at the time of purchase. Please review the Strategy’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Brown Advisory Mid-Cap Growth Strategy highlighted stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) is a leading provider of scientific instruments and analytical and diagnostic solutions. On March 20, 2026, Bruker Corporation (NASDAQ:BRKR) stock closed at $33.30 per share. One-month return of Bruker Corporation (NASDAQ:BRKR) was -15.82%, and its shares lost 25.17% over the past 52 weeks. Bruker Corporation (NASDAQ:BRKR) has a market capitalization of $5.08 billion.
Brown Advisory Mid-Cap Growth Strategy stated the following regarding Bruker Corporation (NASDAQ:BRKR) in its fourth quarter 2025 investor letter:
“Bruker Corporation (NASDAQ:BRKR): Manufactures analytical and medical instruments. Bruker’s (BRKR) shares stabilized in late August after 18 months of decline from a never-ending string of industry headwinds (tariffs, NIH budgets, pharma pricing pressure). Modestly positive momentum returned during the quarter with the announcement of a handful of large equipment orders and positive commentary from other life science tools providers.”
Bruker Corporation (NASDAQ:BRKR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 35 hedge fund portfolios held Bruker Corporation (NASDAQ:BRKR) at the end of the fourth quarter, compared to 50 in the previous quarter. Bruker Corporation (NASDAQ:BRKR) reported Q4 2025 revenue of $977.2 million, flat year over year. While we acknowledge the potential of Bruker Corporation (NASDAQ:BRKR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
